Abstract
Background: In adults with atopic dermatitis (AD), head and/or neck involvement is frequent, bothersome, and impacts quality of life; however, topical corticoid steroids are contraindicated for this difficult-to-treat region. In 2 phase 3 trials of baricitinib for AD, at baseline 98.1% (n = 1215) of patients had head/neck Eczema Severity and Area Index (EASI) > 0. We report treatment efficacy in this population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
